Research programme: monoclonal antibody HUIV 26-derived cancer therapies - Micromet

Drug Profile

Research programme: monoclonal antibody HUIV 26-derived cancer therapies - Micromet

Alternative Names: 2D4; H8

Latest Information Update: 12 Mar 2008

Price : $50

At a glance

  • Originator University of Southern California
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Choroidal neovascularisation; Solid tumours

Most Recent Events

  • 05 May 2006 CancerVax Corporation merged with Micromet AG to form Micromet Inc
  • 15 Nov 2005 Eyetech Pharmaceuticals has been acquired by OSI Pharmaceuticals
  • 09 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top